Louis R. Caplan
Abstract
Although 8 yr have passed since the Food and Drug Administration (FDA) released tissue plasminogen activator (t-PA) for use in the United States to treat patients with acute ischemic stroke, thrombolysis is still very controversial. Clearly, thrombolysis is a step forward but there remain problems with its use, and with the guidelines and policies that direct its application.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Although 8 yr have passed since the Food and Drug Administration (FDA) released tissue plasminogen activator (t-PA) for use in the United States to treat patients with acute ischemic stroke, thrombolysis is still very controversial. Clearly, thrombolysis is a step forward but there remain problems with its use, and with the guidelines and policies that direct its application.
Key concepts: Thrombolysis, Food and drug administration, Tissue plasminogen activator, Medicine, Stroke (engine), Acute stroke, Ischemic stroke, Drug